Description
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL)
Location: CPMC (San Francisco)
Please contact: clinicalresearch@sutterhealth.org for more information about Nektar PROPEL
View study details on ClinicalTrials.gov
Principal Investigator
Co-Investigator(s)
Recruitment Status
Active, Recruiting
Start Date
February 01, 2019
Related Studies
SEER Lung Cancer
SEER-Lung: A Prospective Blood Sample Collection Study to Develop and Validate a Panel
of Proteinbased Biomarkers in Patients with Pulmonary Nodules
Investigator: Tze-Ming Chen, M.D., FCCP
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Using EHR from a large healthcare system in Northern CA, we will study the impact
of smoking, comorbidities, race on COVID-19 infection and disease severity.
Investigator: Jiang Li, Ph.D., MPH